gevokizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pyoderma Gangrenosum
Conditions
Pyoderma Gangrenosum
Trial Timeline
May 1, 2013 → Oct 1, 2015
NCT ID
NCT01882504About gevokizumab
gevokizumab is a phase 2 stage product being developed by XOMA for Pyoderma Gangrenosum. The current trial status is completed. This product is registered under clinical trial identifier NCT01882504. Target conditions include Pyoderma Gangrenosum.
What happened to similar drugs?
1 of 6 similar drugs in Pyoderma Gangrenosum were approved
Approved (1) Terminated (5) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02318914 | Phase 3 | Terminated |
| NCT01950312 | Phase 2 | Completed |
| NCT01882504 | Phase 2 | Completed |
| NCT02293564 | Pre-clinical | Completed |
Competing Products
11 competing products in Pyoderma Gangrenosum
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 35 |
| adalimumab | AbbVie | Phase 3 | 40 |
| sisomicin | Merck | Approved | 35 |
| secukinumab 150 mg (2 injections per dose | Novartis | Phase 2 | 27 |
| Secukinumab | Novartis | Phase 1/2 | 32 |
| Deucravacitinib | Bristol Myers Squibb | Phase 1 | 21 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 22 |
| gevokizumab | XOMA | Phase 3 | 22 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 22 |
| vilobelimab + Placebo | InflaRx | Phase 3 | 22 |
| vilobelimab | InflaRx | Phase 2 | 25 |